Tokyo, Oct. 22 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059491) titled 'Study on Gene Expression Characteristics in Skin Areas Suspected of Having Solar Lentigines or Melasma' on Oct. 21.

Study Type: Observational

Primary Sponsor: Institute - POLA Chemical Industries, Inc.

Condition: Condition - Solar Lentigines, Melasma Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - Establishment of a Novel Classification of Pigmentation Spots and Elucidation of Their Underlying Causes Based on Gene Expression Profiling in Skin Areas Suspected of Solar Lentigines or Melasma Basic objectives2 - Others

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Patients diagnosed with pigmentation spots (such as spots or melasma) at ALOOP CLINIC & LAB, operated by the General Incorporated Association Astronauts

Individuals who have received an explanation of this study, fully understood its contents, and voluntarily agreed to participate by providing informed consent

Healthy individuals aged 18 years or older

Individuals capable of completing, entering, or electronically signing consent forms and related documents Key exclusion criteria - Individuals with a history of severe hepatic disorder, renal disorder, or myocardial infarction Individuals with severe anemia Individuals with a keloid predisposition (those whose scars tend to become raised and red, resembling a worm-like swelling, and heal poorly) Individuals with diabetes mellitus Individuals taking medications that affect skin sampling, such as antiplatelet agents (e.g., aspirin) or anticoagulants Individuals with bleeding or hemostatic disorders Individuals with a history of serious blood-borne infections, such as HIV, hepatitis B, hepatitis C, or syphilis Individuals who have traveled within the past 14 days to areas where infectious diseases are prevalent (as designated by the Ministry of Foreign Affairs' Infectious Disease Risk Information) Individuals with cold symptoms or a fever of 37.5C or higher Any other individuals deemed inappropriate for participation by the principal investigator of the research institution Target Size - 100

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 10 Month 08 Day Date of IRB - 2025 Year 10 Month 09 Day Anticipated trial start date - 2025 Year 11 Month 01 Day Last follow-up date - 2026 Year 09 Month 30 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068036

Disclaimer: Curated by HT Syndication.